Xeris Biopharma Reports Q3 2026 Revenue Growth Driven by Recorlev
Xeris Biopharma (XERS) reported strong third-quarter 2026 financial results, highlighted by a 44% year-over-year increase in total revenue to $107.2 million. The growth was primarily fueled by the rapid expansion of Recorlev, which saw revenue surge 93% to $71.5 million following commercial team expansions and increased patient starts. Despite a slight dip in Gvoke revenue due to a one-time Medicaid adjustment, the company demonstrated improved profitability with an 88% gross margin and adjusted EBITDA rising 77% to $30.8 million. Management significantly raised its long-term outlook, projecting annual revenues exceeding $1 billion by 2030 and accelerating the timeline for Recorlev to reach that milestone.
Tickers: $AXSM
Topics: EBITDA Financial Guidance Product Performance Revenue Growth